Yukari Endo1,2, Satoshi Kuwamoto1, Takahito Ohira3, Michiko Matsushita2, Takahiro Matsushige1, Takahiro Fukuhara4, Shu Nakamoto5, Kazuhiko Hayashi6, Hiroyuki Kugoh3, Yasuaki Hirooka1. 1. Department of Pathology, Tottori University Hospital, Yonago 683-8504, Japan. 2. †Department of Pathobiological Science and Technology, School of Health Sciences, Tottori University Faculty of Medicine, Yonago 683-8503, Japan. 3. ‡Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Yonago 683-8503, Japan. 4. §Division of Otolaryngology, Head and Neck Surgery, Department of Sensory and Motor Organs, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8504, Japan. 5. ||Department of Pathology, Tottori Prefectural Central Hospital, Tottori 680-0901, Japan. 6. ¶Division of Molecular Pathology, Department of Pathology, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.
Abstract
BACKGROUND: Adenoid cystic carcinoma (ACC) is a relatively rare malignant neoplasm that occurs in salivary glands and various other organs. Recent studies have revealed that a significant proportion of ACCs harbor gene alterations involving MYB or MYBL1 (mostly fusions with NFIB) in a mutually-exclusive manner. However, its clinical significance remains to be well-established. METHODS: We investigated clinicopathological and molecular features of 36 ACCs with special emphasis on the significance of MYBL1 alterations. Reverse-transcription polymerase-chain reaction (RT-PCR) and fluorescence in-situ hybridization (FISH) were performed to detect MYB/MYBL1-NFIB fusions and MYBL1 alterations, respectively. Immunohistochemistry was performed to evaluate MYB expression in the tumors. The results were correlated with clinicopathological profiles of the patients. RESULTS: RT-PCR revealed MYB-NFIB and MYBL1-NFIB fusions in 10 (27.8%) and 7 (19.4%) ACCs, respectively, in a mutually-exclusive manner. FISH for MYBL1 rearrangements was successfully performed in 11 cases, and the results were concordant with those of RT-PCR. Immunohistochemically, strong MYB expression was observed in 23 (63.9%) tumors, none of which showed MYBL1 alterations. Clinicopathologically, a trend of a better disease-specific survival was noted in patients with MYBL1 alterations than in those with MYB-NFIB fusions and/or strong MYB expression; however, the difference was not significant. Interestingly, we found tumors with MYBL1 alterations significantly frequently occurred in the mandibular regions (P = 0.012). Moreover, literature review revealed a similar tendency in a previous study. CONCLUSION: Our results suggest that there are some biological or etiological differences between ACCs with MYB and MYBL1 alterations. Moreover, the frequent occurrence of MYBL1-associated ACC in the mandibular regions suggests that MYB immunohistochemistry is less useful in diagnosing ACCs arising in these regions. Further studies are warranted to verify our findings.
BACKGROUND: Adenoid cystic carcinoma (ACC) is a relatively rare malignant neoplasm that occurs in salivary glands and various other organs. Recent studies have revealed that a significant proportion of ACCs harbor gene alterations involving MYB or MYBL1 (mostly fusions with NFIB) in a mutually-exclusive manner. However, its clinical significance remains to be well-established. METHODS: We investigated clinicopathological and molecular features of 36 ACCs with special emphasis on the significance of MYBL1 alterations. Reverse-transcription polymerase-chain reaction (RT-PCR) and fluorescence in-situ hybridization (FISH) were performed to detect MYB/MYBL1-NFIB fusions and MYBL1 alterations, respectively. Immunohistochemistry was performed to evaluate MYB expression in the tumors. The results were correlated with clinicopathological profiles of the patients. RESULTS: RT-PCR revealed MYB-NFIB and MYBL1-NFIB fusions in 10 (27.8%) and 7 (19.4%) ACCs, respectively, in a mutually-exclusive manner. FISH for MYBL1 rearrangements was successfully performed in 11 cases, and the results were concordant with those of RT-PCR. Immunohistochemically, strong MYB expression was observed in 23 (63.9%) tumors, none of which showed MYBL1 alterations. Clinicopathologically, a trend of a better disease-specific survival was noted in patients with MYBL1 alterations than in those with MYB-NFIB fusions and/or strong MYB expression; however, the difference was not significant. Interestingly, we found tumors with MYBL1 alterations significantly frequently occurred in the mandibular regions (P = 0.012). Moreover, literature review revealed a similar tendency in a previous study. CONCLUSION: Our results suggest that there are some biological or etiological differences between ACCs with MYB and MYBL1 alterations. Moreover, the frequent occurrence of MYBL1-associated ACC in the mandibular regions suggests that MYB immunohistochemistry is less useful in diagnosing ACCs arising in these regions. Further studies are warranted to verify our findings.
Authors: Louis B Brill; William A Kanner; André Fehr; Ywonne Andrén; Christopher A Moskaluk; Thomas Löning; Göran Stenman; Henry F Frierson Journal: Mod Pathol Date: 2011-05-13 Impact factor: 7.842
Authors: Robert B West; Christina Kong; Nicole Clarke; Thea Gilks; Joe S Lipsick; Hongbin Cao; Shirley Kwok; Kelli D Montgomery; Sushama Varma; Quynh-Thu Le Journal: Am J Surg Pathol Date: 2011-01 Impact factor: 6.394
Authors: Yoshitsugu Mitani; Jie Li; Pulivarthi H Rao; Yi-Jue Zhao; Diana Bell; Scott M Lippman; Randal S Weber; Carlos Caulin; Adel K El-Naggar Journal: Clin Cancer Res Date: 2010-08-11 Impact factor: 12.531
Authors: Yoshitsugu Mitani; Pulivarthi H Rao; P Andrew Futreal; Dianna B Roberts; Philip J Stephens; Yi-Jue Zhao; Li Zhang; Mutsumi Mitani; Randal S Weber; Scott M Lippman; Carlos Caulin; Adel K El-Naggar Journal: Clin Cancer Res Date: 2011-10-05 Impact factor: 12.531
Authors: Michael Byrne; Justin Wray; Brian Reinert; Yuehan Wu; Jac Nickoloff; Suk-Hee Lee; Robert Hromas; Elizabeth Williamson Journal: Ann N Y Acad Sci Date: 2014-02-16 Impact factor: 5.691
Authors: Marta Persson; Ywonne Andrén; Joachim Mark; Hugo M Horlings; Fredrik Persson; Göran Stenman Journal: Proc Natl Acad Sci U S A Date: 2009-10-19 Impact factor: 11.205
Authors: Christine M Lovly; Abha Gupta; Doron Lipson; Geoff Otto; Tina Brennan; Catherine T Chung; Scott C Borinstein; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Cheryl M Coffin Journal: Cancer Discov Date: 2014-05-29 Impact factor: 39.397
Authors: Eva Lin; Li Li; Yinghui Guan; Robert Soriano; Celina Sanchez Rivers; Sankar Mohan; Ajay Pandita; Jerry Tang; Zora Modrusan Journal: Mol Cancer Res Date: 2009-09-08 Impact factor: 5.852